Lanreótido versus placebo antes de la cirugía para prevenir una complicación quirúrgica llamada fístula pancreática
Un ensayo aleatorizado de lanreótido de fase III para la prevención de la fístula pancreática postoperatoria
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Dana Sparks
- Número de teléfono: 210-614-8808
- Correo electrónico: dsparks@swog.org
Copia de seguridad de contactos de estudio
- Nombre: Andrea Garcia
- Número de teléfono: 210-614-8808
- Correo electrónico: agarcia@swog.org
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Suspendido
- University of Alabama at Birmingham Cancer Center
-
Daphne, Alabama, Estados Unidos, 36526
- Suspendido
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Estados Unidos, 36532
- Suspendido
- Thomas Hospital
-
Mobile, Alabama, Estados Unidos, 36607
- Suspendido
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Estados Unidos, 36571
- Suspendido
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- Suspendido
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Suspendido
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Estados Unidos, 92093
- Reclutamiento
- UC San Diego Moores Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 858-822-5354
- Correo electrónico: cancercto@ucsd.edu
-
Investigador principal:
- Andrew M. Lowy
-
Loma Linda, California, Estados Unidos, 92357
- Suspendido
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles, California, Estados Unidos, 90033
- Suspendido
- USC / Norris Comprehensive Cancer Center
-
San Diego, California, Estados Unidos, 92103
- Suspendido
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19718
- Suspendido
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, Estados Unidos, 19713
- Suspendido
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Suspendido
- Medical Oncology Hematology Consultants PA
-
Wilmington, Delaware, Estados Unidos, 19801
- Suspendido
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin, Florida, Estados Unidos, 33570
- Suspendido
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center - McKinley Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-679-0775
- Correo electrónico: ClinicalTrials@moffitt.org
-
Investigador principal:
- Andrew J. Sinnamon
-
Tampa, Florida, Estados Unidos, 33607
- Suspendido
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Estados Unidos, 33612
- Suspendido
- Moffitt Cancer Center
-
Wesley Chapel, Florida, Estados Unidos, 33544
- Suspendido
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Suspendido
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Estados Unidos, 30308
- Suspendido
- Emory University Hospital Midtown
-
Atlanta, Georgia, Estados Unidos, 30322
- Suspendido
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Estados Unidos, 30303
- Suspendido
- Grady Health System
-
Johns Creek, Georgia, Estados Unidos, 30097
- Suspendido
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
Contacto:
- Site Public Contact
- Número de teléfono: 312-695-1301
- Correo electrónico: cancer@northwestern.edu
-
Investigador principal:
- Akhil Chawla
-
Chicago, Illinois, Estados Unidos, 60612
- Reclutamiento
- University of Illinois
-
Investigador principal:
- Aslam Ejaz
-
Contacto:
- Site Public Contact
- Número de teléfono: 312-355-3046
-
Geneva, Illinois, Estados Unidos, 60134
- Suspendido
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook, Illinois, Estados Unidos, 60523
- Suspendido
- Northwestern Medicine Oak Brook
-
Orland Park, Illinois, Estados Unidos, 60462
- Suspendido
- Northwestern Medicine Orland Park
-
Warrenville, Illinois, Estados Unidos, 60555
- Suspendido
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Suspendido
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Reclutamiento
- University of Kentucky/Markey Cancer Center
-
Investigador principal:
- Michael J. Cavnar
-
Contacto:
- Site Public Contact
- Número de teléfono: 859-257-3379
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Suspendido
- University Medical Center New Orleans
-
-
Maryland
-
Elkton, Maryland, Estados Unidos, 21921
- Suspendido
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Suspendido
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Estados Unidos, 49017
- Suspendido
- Bronson Battle Creek
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Suspendido
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Suspendido
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Suspendido
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon, Michigan, Estados Unidos, 49444
- Suspendido
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Suspendido
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Estados Unidos, 49444
- Suspendido
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Estados Unidos, 49677
- Suspendido
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Suspendido
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Suspendido
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming, Michigan, Estados Unidos, 49519
- Suspendido
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin, Minnesota, Estados Unidos, 56431
- Suspendido
- Riverwood Healthcare Center
-
Baxter, Minnesota, Estados Unidos, 56425
- Suspendido
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Estados Unidos, 56401
- Suspendido
- Essentia Health Saint Joseph's Medical Center
-
Crosslake, Minnesota, Estados Unidos, 56442
- Suspendido
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River, Minnesota, Estados Unidos, 56636
- Suspendido
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Estados Unidos, 56501
- Suspendido
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Estados Unidos, 55805
- Suspendido
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Estados Unidos, 55805
- Suspendido
- Miller-Dwan Hospital
-
Duluth, Minnesota, Estados Unidos, 55805
- Suspendido
- Essentia Health Cancer Center
-
Ely, Minnesota, Estados Unidos, 55731
- Suspendido
- Essentia Health - Ely Clinic
-
Fosston, Minnesota, Estados Unidos, 56542
- Suspendido
- Essentia Health - Fosston
-
Hibbing, Minnesota, Estados Unidos, 55746
- Suspendido
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Estados Unidos, 56649
- Suspendido
- Essentia Health - International Falls Clinic
-
Moose Lake, Minnesota, Estados Unidos, 55767
- Suspendido
- Essentia Health - Moose Lake Clinic
-
Park Rapids, Minnesota, Estados Unidos, 56470
- Suspendido
- Essentia Health - Park Rapids
-
Pequot Lakes, Minnesota, Estados Unidos, 56472
- Suspendido
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River, Minnesota, Estados Unidos, 56474
- Suspendido
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone, Minnesota, Estados Unidos, 55072
- Suspendido
- Essentia Health Sandstone
-
Staples, Minnesota, Estados Unidos, 56479
- Suspendido
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia, Minnesota, Estados Unidos, 55792
- Suspendido
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington, Missouri, Estados Unidos, 63640
- Reclutamiento
- Parkland Health Center - Farmington
-
Investigador principal:
- Bryan A. Faller
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-996-5569
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Reclutamiento
- Sainte Genevieve County Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-996-5569
-
St Louis, Missouri, Estados Unidos, 63131
- Reclutamiento
- Missouri Baptist Medical Center
-
Investigador principal:
- Bryan A. Faller
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-996-5569
-
Sullivan, Missouri, Estados Unidos, 63080
- Reclutamiento
- Missouri Baptist Sullivan Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-996-5569
-
Sunset Hills, Missouri, Estados Unidos, 63127
- Reclutamiento
- BJC Outpatient Center at Sunset Hills
-
Investigador principal:
- Bryan A. Faller
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-996-5569
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Suspendido
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89502
- Suspendido
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston, New Jersey, Estados Unidos, 07039
- Suspendido
- Saint Barnabas Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Suspendido
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Suspendido
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Suspendido
- University of Rochester
-
Syracuse, New York, Estados Unidos, 13210
- Suspendido
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Suspendido
- Carolinas Medical Center/Levine Cancer Institute
-
Concord, North Carolina, Estados Unidos, 28025
- Suspendido
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58103
- Suspendido
- Essentia Health Cancer Center-South University Clinic
-
Fargo, North Dakota, Estados Unidos, 58122
- Suspendido
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Estados Unidos, 58122
- Suspendido
- Sanford Broadway Medical Center
-
Jamestown, North Dakota, Estados Unidos, 58401
- Suspendido
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Suspendido
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus, Ohio, Estados Unidos, 43210
- Suspendido
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Estados Unidos, 45069
- Suspendido
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18104
- Reclutamiento
- Saint Luke's Cancer Center - Allentown
-
Contacto:
- Site Public Contact
- Número de teléfono: 610-776-4714
-
Investigador principal:
- Darius C. Desai
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- Reclutamiento
- Saint Luke's University Hospital-Bethlehem Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 484-503-4151
-
Investigador principal:
- Darius C. Desai
-
Chadds Ford, Pennsylvania, Estados Unidos, 19317
- Suspendido
- Christiana Care Health System-Concord Health Center
-
Easton, Pennsylvania, Estados Unidos, 18045
- Reclutamiento
- Saint Luke's Hospital-Anderson Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-823-5923
- Correo electrónico: ctsucontact@westat.com
-
Investigador principal:
- Darius C. Desai
-
Quakertown, Pennsylvania, Estados Unidos, 18951
- Reclutamiento
- Saint Luke's Hospital - Upper Bucks Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 610-776-4714
-
Investigador principal:
- Darius C. Desai
-
Stroudsburg, Pennsylvania, Estados Unidos, 18360
- Reclutamiento
- Saint Luke's Hospital - Monroe Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-823-5923
- Correo electrónico: ctsucontact@westat.com
-
Investigador principal:
- Darius C. Desai
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- Suspendido
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Suspendido
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Suspendido
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- Suspendido
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Estados Unidos, 38120
- Suspendido
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Suspendido
- University of Vermont and State Agricultural College
-
Burlington, Vermont, Estados Unidos, 05401
- Suspendido
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23235
- Reclutamiento
- VCU Massey Cancer Center at Stony Point
-
Contacto:
- Site Public Contact
- Correo electrónico: ctoclinops@vcu.edu
-
Investigador principal:
- Leopoldo J. Fernandez
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- VCU Massey Comprehensive Cancer Center
-
Investigador principal:
- Leopoldo J. Fernandez
-
Contacto:
- Site Public Contact
- Número de teléfono: 804-628-6430
- Correo electrónico: CTOclinops@vcu.edu
-
Roanoke, Virginia, Estados Unidos, 24033
- Suspendido
- Carilion Roanoke Memorial Hospital
-
Winchester, Virginia, Estados Unidos, 22601
- Suspendido
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Suspendido
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Estados Unidos, 98109
- Suspendido
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, Estados Unidos, 54806
- Suspendido
- Northwest Wisconsin Cancer Center
-
Ashland, Wisconsin, Estados Unidos, 54806
- Suspendido
- Duluth Clinic Ashland
-
Hayward, Wisconsin, Estados Unidos, 54843
- Suspendido
- Essentia Health-Hayward Clinic
-
Hayward, Wisconsin, Estados Unidos, 54843
- Suspendido
- Tamarack Health Hayward Medical Center
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Reclutamiento
- Marshfield Medical Center-Marshfield
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-782-8581
- Correo electrónico: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Jessica A. Wernberg
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- Suspendido
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- Suspendido
- ProHealth Oconomowoc Memorial Hospital
-
Spooner, Wisconsin, Estados Unidos, 54801
- Suspendido
- Essentia Health-Spooner Clinic
-
Superior, Wisconsin, Estados Unidos, 54880
- Suspendido
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Suspendido
- ProHealth Waukesha Memorial Hospital
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Suspendido
- UW Cancer Center at ProHealth Care
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Otros nombres:
Undergo distal pancreatectomy Given SC
Otros nombres:
|
|
Comparador de placebos: Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Otros nombres:
Undergo distal pancreatectomy Given SC
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
Periodo de tiempo: Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of biochemical leak (BL)
Periodo de tiempo: Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
Periodo de tiempo: From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
Periodo de tiempo: At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in pancreatic specific QOL
Periodo de tiempo: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
Periodo de tiempo: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
Periodo de tiempo: Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Periodo de tiempo: Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
Periodo de tiempo: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
Periodo de tiempo: Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Jonathan G Sham, SWOG Cancer Research Network
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Preparaciones farmacéuticas
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Químicos inorgánicos
- Compuestos de cloro
- Soluciones cristaloides
- Soluciones isotónicas
- Soluciones
- Compuestos de sodio
- Cloruros
- Ácido clorhídrico
- Solución salina
- Manejo de muestras
- Cloruro de sodio
- lanreótido
Otros números de identificación del estudio
Otros números de identificación del estudio
- S2408
- UG1CA189974 (Subvención/contrato del NIH de EE. UU.)
- NCI-2024-08361 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (Otro identificador: DCP)
- S2408 (Otro identificador: SWOG)
- S2408 (Otro identificador: CTEP)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .